China’s Global Pharma Supply Chain Operations Resuming In Wake Of Outbreak, USP Says
USP reference standard sales showed slow resumption of API manufacturing in China and less-than-expected API use in India.
You may also be interested in...
Supply chain project shows which drug products are at greatest risk in different scenarios – and which responses would do the most to prevent shortages. Officials from the pharmacopoeial group share how it works and what it can do to help bake in resilience against pandemics, natural disasters, trade wars and shooting wars.
The USP is developing a risk model to assess whether pharmaceutical supply chains are strong or weak based on demand for reference standards.
US agency ensures pharmaceutical companies could manufacture critical medicines domestically even if cut off from China's API suppliers, while stockpiling pandemic medicines during pandemic with Baxter, Fresenius contracts.